Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer.

Nakatani, Yuki; Tanaka, Natsuki; Enami, Tomomi; Minami, Seigo; Okazaki, Tomoko; Komuta, Kiyoshi

Nakatani, Yuki; Tanaka, Natsuki; Enami, Tomomi; Minami, Seigo; Okazaki, Tomoko; Komuta, Kiyoshi.

Afiliação

Nakatani Y; Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan.
Tanaka N; Department of Neurology, Osaka Police Hospital, Osaka, Japan.
Enami T; Department of Neurology, Osaka Police Hospital, Osaka, Japan.
Minami S; Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan.
Okazaki T; Department of Neurology, Osaka Police Hospital, Osaka, Japan.
Komuta K; Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan.

Case Rep Neurol ; 10(3): 346-352, 2018.

Article em En | MEDLINE | ID: mdl-30627102

Palavras-chave

Immune checkpoint inhibitor; Immune-related neurological adverse events; Lambert-Eaton myasthenic syndrome; Nivolumab; Squamous cell carcinoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article